enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
종목 코드 NVNO
회사 이름enVVeno Medical Corp
상장일May 31, 2018
CEOBerman (Robert A)
직원 수37
유형Ordinary Share
회계 연도 종료May 31
주소70 Doppler
도시IRVINE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호92618
전화19492612900
웹사이트https://envveno.com/
종목 코드 NVNO
상장일May 31, 2018
CEOBerman (Robert A)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음